Interferon variables
| Variable . | N . | Value . |
|---|---|---|
| Number receiving IFN | 489 | |
| Number returning supplementary IFN form | 324 (66%) | |
| Interval from diagnosis to start of IFN, median | 291 | 1.8 mo |
| Duration of IFN therapy, median | 305 | 9.6 mo |
| Starting dose, median | 247 | 3 MU/d |
| Maximum dose, median | 242 | 8 MU/d |
| Time to best response, median | 145 | 6.7 mo |
| Best response to IFN | 303 | |
| Complete response | 2% | |
| Partial response | 4% | |
| Minor response | 13% | |
| Hematologic response, unknown cytogenetics | 19% | |
| Hematologic response, no cytogenetics | 42% | |
| None | 20% | |
| Interval between IFN discontinuation and transplant, median | 293 | 74 d |
| Toxicity | 278 | |
| None | 41% | |
| Minor | 47% | |
| Major | 12% | |
| Reason for stopping IFN | 320 | |
| Transplant | 62% | |
| Did not tolerate | 14% | |
| No/inadequate response | 17% | |
| Progression after response | 3% | |
| Other | 4% | |
| Received IFN more than 6 mo | 246 | 70% |
| Received IFN within 90 d of transplant | 293 | 56% |
| Additional medications | ||
| Hydroxyurea | 318 | 71% |
| Busulfan | 308 | 1% |
| Cytarabine | 308 | 5% |
| Variable . | N . | Value . |
|---|---|---|
| Number receiving IFN | 489 | |
| Number returning supplementary IFN form | 324 (66%) | |
| Interval from diagnosis to start of IFN, median | 291 | 1.8 mo |
| Duration of IFN therapy, median | 305 | 9.6 mo |
| Starting dose, median | 247 | 3 MU/d |
| Maximum dose, median | 242 | 8 MU/d |
| Time to best response, median | 145 | 6.7 mo |
| Best response to IFN | 303 | |
| Complete response | 2% | |
| Partial response | 4% | |
| Minor response | 13% | |
| Hematologic response, unknown cytogenetics | 19% | |
| Hematologic response, no cytogenetics | 42% | |
| None | 20% | |
| Interval between IFN discontinuation and transplant, median | 293 | 74 d |
| Toxicity | 278 | |
| None | 41% | |
| Minor | 47% | |
| Major | 12% | |
| Reason for stopping IFN | 320 | |
| Transplant | 62% | |
| Did not tolerate | 14% | |
| No/inadequate response | 17% | |
| Progression after response | 3% | |
| Other | 4% | |
| Received IFN more than 6 mo | 246 | 70% |
| Received IFN within 90 d of transplant | 293 | 56% |
| Additional medications | ||
| Hydroxyurea | 318 | 71% |
| Busulfan | 308 | 1% |
| Cytarabine | 308 | 5% |